Randomized trials demonstrated the beneficial effects of sodium-glucose co-transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction [4,5,6]. Here, SLC5A2 is linked to type 2 diabetes mellitus.